Nausea on a GLP-1: 44 percent on Wegovy and 29 percent on Zepbound
Nausea reached 44 percent on Wegovy 2.4 mg and 29 percent on Zepbound 10 mg in the clinical trials printed on their FDA labels, against 16 and 8 percent on placebo. GLP Chart read both labels on DailyMed, revised June and August 2026.
If the monthly price is the problem, two cash programs to check.
No insurance needed.
- SnagRxSponsored$99 a monthcompounded semaglutideCheck price →SnagRx's homepage shows its 12-month prepaid prices first
- MedviSponsored$299 a monthFirst month $179compounded semaglutideCheck price →Straight to MEDVi's GLP-1 sign-up
The prevention protocol has the dose steps, the meal timing and the trial numbers behind each move.
| Label and dose | Who was in the trial | On the drug | On placebo |
|---|---|---|---|
| Wegovy 2.4 mg (June 2026 label) | adults with obesity or overweight, n=2,116 | 44% | 16% (n=1,261) |
| Wegovy 2.4 mg (June 2026 label, dose-comparison trials) | adults with obesity in the two clinical trials comparing the maintenance doses, n=304 | 35% | 13% (n=303) |
| Wegovy 7.2 mg (June 2026 label, dose-comparison trials) | adults with obesity in the two clinical trials comparing the maintenance doses, n=1,311 | 39% | 13% (n=303) |
| Zepbound 5 mg (August 2026 label) | adults with obesity or overweight, n=630 | 25% | 8% (n=958) |
| Zepbound 10 mg (August 2026 label) | adults with obesity or overweight, n=948 | 29% | 8% (n=958) |
| Zepbound 15 mg (August 2026 label) | adults with obesity or overweight, n=941 | 28% | 8% (n=958) |
| Ozempic 0.5 mg (June 2026 label) | adults with type 2 diabetes, n=260 | 15.8% | 6.1% (n=262) |
| Ozempic 1 mg (June 2026 label) | adults with type 2 diabetes, n=261 | 20.3% | 6.1% (n=262) |
| Mounjaro 5 mg (August 2026 label) | adults with type 2 diabetes, n=237 | 12% | 4% (n=235) |
| Mounjaro 10 mg (August 2026 label) | adults with type 2 diabetes, n=240 | 15% | 4% (n=235) |
| Mounjaro 15 mg (August 2026 label) | adults with type 2 diabetes, n=241 | 18% | 4% (n=235) |
The dose moves it, but not in a straight line
On three of the four labels the rate climbs with the dose. Ozempic reads 15.8 percent at 0.5 mg and 20.3 percent at 1 mg. Mounjaro reads 12 percent at 5 mg and 18 percent at 15 mg. Wegovy's own high-dose table reads 35 percent at 2.4 mg and 39 percent at 7.2 mg.
Zepbound is the exception. Its table reads 25 percent at 5 mg, 29 percent at 10 mg and 28 percent at 15 mg, so the peak is the middle step rather than the top one. That matters if you are at 10 mg and being told the next step will be worse. On this label the 15 mg column is a point lower than the 10 mg one.
The two weight-management labels also sit far above the two diabetes labels for the same molecules. Wegovy is 44 percent and Ozempic tops out at 20.3 percent. The doses differ and so do the trial populations. Ozempic's table also cuts at 5 percent, so a lower rate never reaches it. Read each figure against its own placebo column rather than against the other drug.
What a slower ladder costs
Neither label says what the slower route costs. On some programs the lower dose is the cheaper one and on others the price does not move at all.
| Drug | Cheapest program we track | At the maintenance dose | At the top dose it publishes |
|---|---|---|---|
| Wegovy | Knownwell | $299 a month | Publishes one figure only |
| Zepbound | Sam's Club Member Health | $399 a month | $449 a month, with refills inside 45 days |
LifeMD charges $200 a month more at the top of its ladder than at the dose you stay on. Ask the program what it charges at each dose before you agree to climb.
Compare every program at its real maintenance price →
What the labels tell a prescriber
- Wegovy's label tells a prescriber what to do when a patient does not tolerate a dose:
If patients do not tolerate a dose during dosage escalation, consider delaying dosage escalation for 4 weeks.
Wegovy label, section 2, dosage and administration - Zepbound's label answers the same problem at the maintenance dose:
If patients do not tolerate a maintenance dosage, consider a lower maintenance dosage.
Zepbound label, section 2 - Zepbound's label also records when those reports came in:
The majority of nausea, vomiting, and/or diarrhea events occurred during dose escalation and decreased over time.
Zepbound label, section 6.1 - Ozempic and Mounjaro carry no tolerability sentence at all. On both labels every step past the first turns on needing more glycemic control, not on how the patient feels.Ozempic label, section 2 and Mounjaro label, section 2
- The Wegovy label carries a separate instruction for its tablet:
If patients do not tolerate the 25 mg once daily maintenance dosage, consider switching to WEGOVY injection 1.7 mg once weekly.
Wegovy label, section 2 - In the pooled STEP 1 to 3 trials, 98.1 percent of the gut reactions on semaglutide 2.4 mg were mild or moderate, and 4.3 percent of patients stopped the drug over one.Wharton 2022, DOI 10.1111/dom.14551
How long it lasts
In SURMOUNT-1 the gut reactions came mostly inside the 20 week escalation period. The paper's own sentence reads: most were mild to moderate in severity, occurring primarily during dose escalation
STEP 1 puts it this way: typically transient and mild-to-moderate in severity and subsided with time
Neither paper published a day count.Jastreboff 2022, DOI 10.1056/NEJMoa2206038; Wilding 2021, DOI 10.1056/NEJMoa2032183
What a dose change costs
Both weight-management labels answer a tolerability problem the same way, by slowing the ladder or stepping back down. What that does to the bill depends on the program. Shed lists $199 a month, the same figure at every dose. Strut Health lists $149 a month, with auto-refill. Medvi lists $299 a month, after $179 for the first month. None of the three sets its price by the dose, so holding a step costs the same as taking it.
The oral Wegovy tablet carries no nausea figure. Its label prints no reaction table, only a sentence saying the common reactions looked like the injection's.
Reflux and heartburn sit in the same rows
Wegovy's label prints acid reflux at 5 percent at 2.4 mg, against 3 percent on placebo, and indigestion at 9 percent at 2.4 mg, against 3 percent on placebo. Zepbound's prints acid reflux at 4 percent at 5 mg, 4 percent at 10 mg and 5 percent at 15 mg, against 2 percent on placebo, and indigestion at 9 percent at 5 mg, 9 percent at 10 mg and 10 percent at 15 mg, against 4 percent on placebo.
Ozempic's table cuts at a rate neither reaches, so its label prints both under the table instead: acid reflux at 1.9 percent on 0.5 mg and 1.5 percent on 1 mg, against 0 percent on placebo, and indigestion at 3.5 percent on 0.5 mg and 2.7 percent on 1 mg, against 1.9 percent on placebo. No label in the set prints an instruction aimed at reflux, and none names an antacid.
Frequently asked questions
How common is nausea on a GLP-1?
The FDA labels report it as the most common adverse reaction on both molecules. Wegovy's label puts nausea at 44 percent at 2.4 mg against 16 percent on placebo. Zepbound's puts it at 25 percent at 5 mg, 29 percent at 10 mg and 28 percent at 15 mg, against 8 percent on placebo.
Does a higher dose mean more nausea?
Mostly, and not evenly. Ozempic runs 15.8 percent at 0.5 mg and 20.3 percent at 1 mg. Mounjaro runs 12 percent at 5 mg and 18 percent at 15 mg. Wegovy's own high-dose table reads 35 percent at 2.4 mg and 39 percent at 7.2 mg. Zepbound is the exception: it peaks at 29 percent at 10 mg and reads 28 percent at 15 mg.
What does the label say to do about it?
Wegovy's label says that if a patient does not tolerate a dose during escalation, consider delaying escalation for 4 weeks. Zepbound's says that if a patient does not tolerate a maintenance dosage, consider a lower maintenance dosage. Both sentences are addressed to the prescriber.
Does holding at a lower dose cost less?
It depends on the program. Some publish one price at every dose and some charge more at each step up, so the same clinical decision saves money on one plan and nothing on another.
Is the nausea permanent?
The labels do not answer that. They report how many people in each trial arm had the reaction at any point, not how long it lasted. Anyone still unable to keep fluids down should call the prescriber the same day.
Every dosage sentence on this page is written to a prescriber, not to you. Holding a dose, dropping back or stopping changes what the drug is doing. Take the label language to the appointment.
Sources
Evidence checked August 31, 2026
Every figure above is taken from the document beside it, the FDA label or the trial that produced it, so you can read the source instead of trusting us. No clinician reviews these pages. What that means.
- The 44 percent Wegovy figure, the 35 against 39 percent comparison at 2.4 mg and 7.2 mg, and the tolerability sentence about delaying escalationFDA prescribing information for Wegovy, injection and tablets (DailyMed, revised June 2026)
- The Zepbound rates at 5 mg, 10 mg and 15 mg and the sentence about considering a lower maintenance dosageFDA prescribing information for Zepbound (DailyMed, revised August 2026)
- The Ozempic rates at 0.5 mg and 1 mg in adults with type 2 diabetesFDA prescribing information for Ozempic injection (DailyMed, revised June 2026)
- The Mounjaro rates at 5 mg, 10 mg and 15 mg in adults with type 2 diabetesFDA prescribing information for Mounjaro (DailyMed, revised August 2026)
- The share of gut reactions that were mild or moderate and the share of patients who stopped over oneWharton S et al. Diabetes Obes Metab 2022;24(1):94-105
- The SURMOUNT-1 dose-escalation period and the paper's own description of when the reactions cameJastreboff AM et al. N Engl J Med 2022;387(3):205-216
- The STEP 1 description of the gut reactions as transientWilding JPH et al. N Engl J Med 2021;384(11):989-1002